KRYSTAL BIOTECH INC (KRYS) Forecast, Price Target & Analyst Ratings
NASDAQ:KRYS • US5011471027
262.73 USD
+4.08 (+1.58%)
Last: Mar 10, 2026, 12:37 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KRYSTAL BIOTECH INC (KRYS).
Forecast Snapshot
Consensus Price Target
$313.24
+ 19.23% Upside
Next Earnings Forecast
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate$1.37
Revenue Estimate113.8M
ChartMill Buy Consensus
87.06%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$313.24
Upside
+ 19.23%
From current price of $262.73 to mean target of $313.24, Based on 17 analyst forecasts
Low
$217.15
Median
$320.28
High
$389.55
Price Target Revisions
1 Month
5.60%
3 Months
38.05%
Price Target Summary
17 Wall Street analysts provided a forecast for the next 12 months for KRYS. The average price target is 313.24 USD. This implies a price increase of 19.23% is expected in the next year compared to the current price of 262.73.
The average price target has been revised upward by 38.05% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.06%
KRYS was analyzed by 17 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about KRYS.
In the previous month the buy percentage consensus was at a similar level.
KRYS was analyzed by 17 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-02-18 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-17 | Jefferies | Maintains | Buy -> Buy |
| 2026-02-02 | Goldman Sachs | Maintains | Buy -> Buy |
| 2026-01-22 | B of A Securities | Maintains | Buy -> Buy |
| 2026-01-12 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-09 | TD Cowen | Maintains | Buy -> Buy |
| 2026-01-09 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-06 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-11-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-04 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-10-17 | B of A Securities | Maintains | Buy -> Buy |
| 2025-09-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-22 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-05 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-07-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-22 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-10 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-07-01 | Clear Street | Initiate | Buy |
| 2025-06-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate$1.37
Revenue Estimate113.8M
Revenue Q2Q29.05%
EPS Q2Q13.80%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
-4.39%
Revenue (3 Months)
-4.54%
EPS (1 Month)
-11.45%
EPS (3 Months)
-8.14%
Next Earnings Summary
KRYS is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is 1.37 USD and the consensus revenue estimate is 113.80M USD.
The next earnings revenue estimate has been revised downward by 4.54% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 50.699M | 290.515M 473.02% | 389.13M 33.94% | 548.21M 40.88% | 740.96M 35.16% | 972.43M 31.24% | 1.233B 26.80% | 1.495B 21.25% | 1.718B 14.92% | 1.422B -17.23% | 1.83B 28.69% | |
| EBITDA YoY % growth | -92.22M 20.60% | 109.162M 218.37% | 167.019M 53.00% | 238.36M 42.71% | 326.98M 37.18% | 641.27M 96.12% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -97.227M 19.11% | 103.195M 206.14% | 161.295M 56.30% | 247.79M 53.63% | 335.59M 35.43% | 509.09M 51.70% | 830.46M 63.13% | 1.059B 27.52% | 1.255B 18.51% | 1.053B -16.10% | 1.329B 26.21% | |
| Operating Margin | -191.77% | 35.52% | 41.45% | 45.20% | 45.29% | 52.35% | 67.35% | 70.84% | 73.05% | 74.05% | 72.62% | |
| EPS YoY % growth | -3.40 24.61% | 2.99 187.94% | 6.85 129.10% | 7.87 14.92% | 11.13 41.39% | 15.14 36.02% | 25.87 70.91% | 32.13 24.18% | 36.72 14.30% | 20.06 -45.37% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.37 13.80% | 1.70 31.52% | 2.24 -15.87% | 2.35 38.40% | 2.92 113.61% | 3.55 109.22% | 4.12 84.14% | 4.86 106.36% |
| Revenue Q2Q % growth | 113.8M 29.05% | 130.32M 35.69% | 153.71M 57.17% | 173.46M 61.95% | 178.2M 56.59% | 208.3M 59.84% | 233.81M 52.11% | 266.08M 53.40% |
| EBITDA Q2Q % growth | 46.016M 22.43% | 50.898M 21.00% | 71.091M 56.12% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 38.469M 6.34% | 47.614M 21.13% | 55.691M 34.60% | 72.726M 64.28% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
30.26%
EPS Next 5 Year
36.22%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
34.98%
Revenue Next 5 Year
30.47%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
57.38%
EBIT Next 5 Year
N/A
KRYSTAL BIOTECH INC / KRYS Forecast FAQ
What do analysts expect the price target to be for KRYSTAL BIOTECH INC (KRYS)?
17 analysts have analysed KRYS and the average price target is 313.24 USD. This implies a price increase of 19.23% is expected in the next year compared to the current price of 262.73.
What is the next earnings date for KRYS stock?
KRYSTAL BIOTECH INC (KRYS) will report earnings on 2026-05-04, before the market open.
What are the consensus estimates for KRYS stock next earnings?
The consensus EPS estimate for the next earnings of KRYSTAL BIOTECH INC (KRYS) is 1.37 USD and the consensus revenue estimate is 113.80M USD.
Can you provide the analyst count for KRYSTAL BIOTECH INC stock?
The number of analysts covering KRYSTAL BIOTECH INC (KRYS) is 17.